Group 1 - The Hong Kong Innovation Drug ETF (159570) has experienced a decline for four consecutive days, with a nearly 1% drop and a trading volume exceeding 1.15 billion HKD, indicating rapid capital inflow [1] - As of January 19, the latest scale of the Hong Kong Innovation Drug ETF (159570) has surpassed 25.4 billion HKD, leading its peers in the same category [1] - The weighted stocks of the ETF have mostly shown negative performance, with notable declines including Innovent Biologics down over 3% and Hengrui Medicine down over 2% [3][4] Group 2 - At the JPMorgan Conference, over 20 Chinese pharmaceutical companies showcased their innovations, with Hengrui expected to see a 25%+ growth in innovative drug revenue by 2026 [5] - The domestic biotech sector is experiencing a surge in business development (BD) activities, with significant deals such as the 5.6 billion USD global exclusive license agreement between Rongchang Biopharma and AbbVie [5][6] - A domestic innovative drug company has projected a revenue of approximately 45.46 billion RMB for 2025, reflecting a year-on-year growth of 15.84%, with a substantial increase in net profit [7]
创新药迎JPM+BD+业绩预增多重催化！港股通创新药ETF(159570)跌近1%连续第四日回调，超1亿元资金逢跌布局！
Xin Lang Cai Jing·2026-01-20 07:05